TABLE 1.
Mean (standard deviation) for demographics and clinical assessments
| Descriptive | P‐values for pairwise tests | |||||
|---|---|---|---|---|---|---|
| HC | PD | PSP | HC vs. PD | HC vs. PSP | PD vs. PSP | |
| Age (y) | 65.5 (5.5) | 67.4 (7.4) | 69.7 (7.7) | 0.579 | 0.163 | 0.576 |
| Education (y) | 14.8 (3.1) | 14.1 (2.3) | 12.3 (2.8) | 0.603 | 0.02 | 0.13 |
| Male/female | 13/11 | 18/7 | 8/6 | 0.196 | 0.859 | 0.345 |
| MMSE | 29.75 (0.53) | 29.52 (0.65) | 28.5 (1.74) | 0.685 | <0.001 | 0.007 |
| MoCA | 28.58 (1.44) | 27.96 (1.88) | 24 (3.94) | 0.628 | <0.001 | <0.001 |
| ACE‐R total | 97.71 (3.25) | 95.40 (3.61) | 87.21 (7.17) | 0.182 | <0.001 | <0.001 |
| Apathy Scale | 10.38 (5.25) | 12.44 (5.43) | 20 (9.49) | 0.508 | <0.001 | 0.003 |
| BIS | 55.71 (9.56) | 58.18 (10.31) | 63.86 (12.44) | 0.692 | 0.064 | 0.248 |
| HADS depression | 2.83 (2.84) | 4.24 (2.73) | 7.43 (4.27) | 0.273 | <0.001 | 0.01 |
| HADS anxiety | 4.29 (3.53) | 5.04 (3.16) | 6.57 (3.2) | 0.711 | 0.11 | 0.356 |
| RBDSQ | – | 5.48 (3.65) | 3.07 (1.82) | – | – | 0.027 |
| Disease duration (y) | – | 5 (3.05) | 4.24 (2.68) | – | – | 0.438 |
| LEDD | – | 644.3 (499.36) | 323.57 (389.4) | 0.038 | ||
| UPDRS‐III | – | 28.36 (11.98) | 33.07 (6.96) | – | – | 0.187 |
| PSPRS | – | – | 30.79 (9.11) | – | – | – |
Group difference in sex was examined using χ2 test. A one‐way analysis of variance was used for group difference with post hoc Tukey’s honestly significant difference P‐values provided for pairwise comparisons. Significant P‐values (P < 0.0016, equivalent to P < 0.05, with Bonferroni correction for multiple comparisons of all tests on demographics and clinical assessments) are highlighted in bold font.
RBDSQ, disease duration, and UPDRS‐III were compared with independent sample t test between PD and PSP.
Abbreviations: HC, healthy control; PD, Parkinson's disease; PSP, progressive supranuclear palsy; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; ACE‐R, Addenbrooke's Cognitive Examination‐Revised; BIS, Barratt Impulsiveness Scale; HADS, Hamilton Anxiety and Depression Scale; RBDSQ, REM Sleep Behavior Disorder Screening Questionnaire; LEDD, levodopa equivalent daily dose; UPDRS, Unified Parkinson's Disease Rating Scale; PSPRS, Progressive Supranuclear Palsy Rating Scale.